Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study Evaluating the Safety and Efficacy of IL-15-armored Novel CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia

NCT07509086 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT07509086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07509086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study Evaluating the Safety and Efficacy of IL-15-armored Novel CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia
Lead sponsor
The First Hospital of Jilin University
Phase
Phase 2
Overall status
Recruiting
Start date
December 29, 2025
Completion date
July 15, 2029
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell leukemia (pcl), relapsed/refractory multiple myeloma